Jason Clark

2.0k total citations
29 papers, 1.2k citations indexed

About

Jason Clark is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jason Clark has authored 29 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jason Clark's work include Pancreatic and Hepatic Oncology Research (6 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cancer Genomics and Diagnostics (4 papers). Jason Clark is often cited by papers focused on Pancreatic and Hepatic Oncology Research (6 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cancer Genomics and Diagnostics (4 papers). Jason Clark collaborates with scholars based in United States, Italy and Australia. Jason Clark's co-authors include Lance Leopold, Peter J. O’Dwyer, Janet Maleski, Thomas F. Gajewski, Gregory L. Beatty, Richard Schaub, Jack Shi, Robert Newton, Robert A. Beckman and Cong Chen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Nature Reviews Drug Discovery.

In The Last Decade

Jason Clark

28 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jason Clark United States	16	645	311	271	190	143	29	1.2k
A. Nawa Japan	21	385 0.6×	461 1.5×	153 0.6×	170 0.9×	109 0.8×	30	1.3k
Yong Wha Moon South Korea	22	918 1.4×	658 2.1×	301 1.1×	335 1.8×	685 4.8×	69	1.8k
Jessica Bauer United States	16	595 0.9×	686 2.2×	174 0.6×	235 1.2×	114 0.8×	40	1.3k
Vito Barbieri Italy	22	628 1.0×	671 2.2×	193 0.7×	279 1.5×	171 1.2×	46	1.5k
Satoshi Takakura Japan	18	291 0.5×	445 1.4×	211 0.8×	141 0.7×	112 0.8×	37	1.1k
Ling Gu China	22	395 0.6×	1.0k 3.3×	202 0.7×	485 2.6×	96 0.7×	57	1.4k
Daya Luo China	15	225 0.3×	513 1.6×	137 0.5×	318 1.7×	112 0.8×	48	907
Jeannine Villella United States	16	388 0.6×	523 1.7×	311 1.1×	176 0.9×	58 0.4×	43	1.2k
Jean‐Philippe Guégan France	17	399 0.6×	320 1.0×	263 1.0×	117 0.6×	118 0.8×	40	822

Countries citing papers authored by Jason Clark

Since Specialization

Citations

This map shows the geographic impact of Jason Clark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason Clark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason Clark more than expected).

Fields of papers citing papers by Jason Clark

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason Clark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason Clark. The network helps show where Jason Clark may publish in the future.

Co-authorship network of co-authors of Jason Clark

This figure shows the co-authorship network connecting the top 25 collaborators of Jason Clark. A scholar is included among the top collaborators of Jason Clark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason Clark. Jason Clark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Necchi, Andrea, Michiel S. van der Heijden, Avivit Peer, et al.. (2024). Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study. BMC Cancer. 23(S1). 1252–1252. 6 indexed citations

Çiçin, İrfan, Elizabeth R. Plimack, Howard Gurney, et al.. (2024). Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study. BMC Cancer. 23(S1). 1256–1256. 10 indexed citations

Talpaz, Moshe, Josef T. Prchal, Lawrence B. Afrin, et al.. (2021). Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 – 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study. Clinical Lymphoma Myeloma & Leukemia. 22(5). 336–346. 10 indexed citations

Clark, Jason, Andrew Whiting, & Peter McCaffery. (2020). Retinoic acid receptor-targeted drugs in neurodegenerative disease. Expert Opinion on Drug Metabolism & Toxicology. 16(11). 1097–1108. 22 indexed citations

Hurwitz, Herbert I., Eric Van Cutsem, Johanna C. Bendell, et al.. (2018). Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Investigational New Drugs. 36(4). 683–695. 87 indexed citations

Hurwitz, Herbert I., Eric Van Cutsem, Johanna C. Bendell, et al.. (2017). Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2).. Journal of Clinical Oncology. 35(4_suppl). 343–343. 18 indexed citations

Hurwitz, Herbert I., Nikhil Uppal, Stephanie A. Wagner, et al.. (2015). Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. Journal of Clinical Oncology. 33(34). 4039–4047. 237 indexed citations

Hurwitz, H., Nikhil Uppal, J. C. Bendell, et al.. (2014). Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial. Annals of Oncology. 25. ii115–ii115. 2 indexed citations

Seymour, John F., D. W. Kim, Abebe Haregewoin, et al.. (2014). A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer Journal. 4(8). e238–e238. 56 indexed citations

10.

Mascarenhas, John, Moshe Talpaz, Vikas Gupta, et al.. (2014). Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis. Blood. 124(21). 714–714. 7 indexed citations

11.

Beatty, Gregory L., Peter J. O’Dwyer, Jason Clark, et al.. (2013). Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies.. Journal of Clinical Oncology. 31(15_suppl). 3025–3025. 34 indexed citations

12.

Chiappori, Alberto, Luigi Aurisicchio, Ansuman Bagchi, et al.. (2013). Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. Journal of Translational Medicine. 11(1). 62–62. 64 indexed citations

13.

Giles, Francis J., Ronan Swords, Arnon Nagler, et al.. (2012). MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia. Leukemia. 27(1). 113–117. 55 indexed citations

14.

Beckman, Robert A., Jason Clark, & Cong Chen. (2011). Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Nature Reviews Drug Discovery. 10(10). 735–748. 76 indexed citations

15.

Traynor, Anne M., Glenn Liu, Keith T. Flaherty, et al.. (2010). Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 67(2). 305–314. 73 indexed citations

16.

Harding, Gale, David Cella, Don Robinson, et al.. (2007). Symptom burden among patients with Renal Cell Carcinoma (RCC): content for a symptom index. Health and Quality of Life Outcomes. 5(1). 34–34. 42 indexed citations

17.

Ouriel, Kenneth, Flavio Castañeda, Thomas McNamara, et al.. (2004). Reteplase Monotherapy and Reteplase/Abciximab Combination Therapy in Peripheral Arterial Occlusive Disease: Results from the RELAX Trial. Journal of Vascular and Interventional Radiology. 15(3). 229–238. 34 indexed citations

18.

Clark, Jason, et al.. (1992). Safety study of a beef-based chewable tablet formulation of ivermectin and pyrantel pamoate in growing dogs, pups, and breeding adult dogs. American Journal of Veterinary Research. 53(4). 608–612. 2 indexed citations

19.

Clark, Jason, et al.. (1992). Pharmacokinetics of [³H]‐ivermectin in the dog following oral administration of a beef‐based chewable formulation containing ivermectin alone or in combination with pyrantel pamoate. Journal of Veterinary Pharmacology and Therapeutics. 15(2). 217–220. 4 indexed citations

20.

Clark, Jason, et al.. (1992). Efficacy of ivermectin and pyrantel pamoate combined in a chewable formulation against heartworm, hookworm, and ascarid infections in dogs. American Journal of Veterinary Research. 53(4). 517–520. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact